{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:36:16Z","timestamp":1761597376695},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T00:00:00Z","timestamp":1348617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10067-012-2091-4","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T22:11:58Z","timestamp":1348611118000},"page":"61-66","source":"Crossref","is-referenced-by-count":16,"title":["Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases"],"prefix":"10.1007","volume":"32","author":[{"given":"\u013dubom\u00edr","family":"Tom\u00e1\u0161","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivica","family":"Laz\u00farov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00fddia","family":"Pundov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Oetterov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Zakuciov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darina","family":"Petr\u00e1\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Studen\u010dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,26]]},"reference":[{"issue":"3","key":"2091_CR1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","volume":"52","author":"H Maradit-Kremers","year":"2005","unstructured":"Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722\u2013732","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2091_CR2","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar428","volume":"4","author":"PH Dessein","year":"2002","unstructured":"Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4(5):R5","journal-title":"Arthritis Res"},{"issue":"1","key":"2091_CR3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.22482","volume":"57","author":"MA Gonzalez-Gay","year":"2007","unstructured":"Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pi\u00f1eiro A, Garcia-Porrua C, Miranda-Filloy JA et al (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57(1):125\u2013132","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2091_CR4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.crohns.2010.09.008","volume":"5","author":"J Haapam\u00e4ki","year":"2011","unstructured":"Haapam\u00e4ki J, Roine RP, Turunen U, F\u00e4rkkil\u00e4 MA, Arkkila PE (2011) Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 5(1):41\u201347","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2091_CR5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214(2):149\u2013160","journal-title":"J Pathol"},{"issue":"22","key":"2091_CR6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Eng J Med 343(22):1594\u20131602","journal-title":"N Eng J Med"},{"issue":"6","key":"2091_CR7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","volume":"46","author":"J Braun","year":"2007","unstructured":"Braun J, McHugh N, Singh A, Wajdula JS, Sato R (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50\u00a0mg once-weekly and 25\u00a0mg twice-weekly. Rheumatology 46(6):999\u20131004","journal-title":"Rheumatology"},{"issue":"9317","key":"2091_CR8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317):1541\u20131549","journal-title":"Lancet"},{"key":"2091_CR9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/14740338.7.5.617","volume":"5","author":"R Caviglia","year":"2008","unstructured":"Caviglia R, Boskoski I, Cicala M (2008) Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 5:617\u2013632","journal-title":"Expert Opin Drug Saf"},{"key":"2091_CR10","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"key":"2091_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","volume":"86","author":"SD Anker","year":"2002","unstructured":"Anker SD, Coats AJS (2002) How to RECOVER FROM RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86:123\u2013130","journal-title":"Int J Cardiol"},{"key":"2091_CR12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","volume":"103","author":"B Bozkurt","year":"2001","unstructured":"Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM et al (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:1044\u20131047","journal-title":"Circulation"},{"issue":"5","key":"2091_CR13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","volume":"116","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116(5):305\u2013311","journal-title":"Am J Med"},{"key":"2091_CR14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","volume":"46","author":"JR Curtis","year":"2007","unstructured":"Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D et al (2007) Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-\u03b1 antagonists. Rheumatology 46:1688\u20131693","journal-title":"Rheumatology"},{"key":"2091_CR15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","volume":"58","author":"J Listing","year":"2008","unstructured":"Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S et al (2008) Does tumor necrosis factor-\u03b1 inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667\u2013677","journal-title":"Arthritis Rheum"},{"key":"2091_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","volume":"27","author":"J Cole","year":"2007","unstructured":"Cole J, Busti A, Kazi S (2007) The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 27:369\u2013373","journal-title":"Rheumatol Int"},{"key":"2091_CR17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/ard.2009.119412","volume":"69","author":"MJ Peters","year":"2010","unstructured":"Peters MJ, Welsh P, MsInnes IB, Wolbink G, Dijkmans BA, Satttar N et al (2010) Tumor necrosis factor alpha blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 69:1281\u20131285","journal-title":"Ann Rheum Dis"},{"key":"2091_CR18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303\u20131309","journal-title":"Circulation"},{"issue":"1","key":"2091_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10067-005-1117-6","volume":"25","author":"F Brunner","year":"2006","unstructured":"Brunner F, Kunz A, Weber U, Kissling R (2006) Ankylosing pondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15\u00a0years than in normal population? Clin Rheumatol 25(1):24\u201329","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2091_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1440-1746.2006.04384.x","volume":"22","author":"G Bragagni","year":"2007","unstructured":"Bragagni G, Brogna R, Franceschetti P, Zoli G (2007) Cardiac involvement in Crohn's disease: echocardiographic study. J Gastroenterol Hepatol 22(1):18\u201322","journal-title":"J Gastroenterol Hepatol"},{"key":"2091_CR21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/ard.2010.141523","volume":"70","author":"SA Provan","year":"2011","unstructured":"Provan SA, Semb AG, Hisdal J, Stranden E, Agewall S, Dagfinrud H et al (2011) Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 70:812\u2013817","journal-title":"Ann Rheum Dis"},{"key":"2091_CR22","first-page":"1497","volume":"63","author":"JM Davis 3rd","year":"2011","unstructured":"Davis JM 3rd, Knutson KL, Straubauch MA, Crowson CS, Therneau TM, Wettstein PJ et al (2011) A singature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum 63:1497\u20131506","journal-title":"Arthritis Rheum"},{"key":"2091_CR23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00001573-199905000-00003","volume":"14","author":"G Torre-Amione","year":"1999","unstructured":"Torre-Amione G, Bozkurt B, Deswal A, Mann DL (1999) An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 14:206\u2013210","journal-title":"Curr Opin Cardiol"},{"key":"2091_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1006\/jmcc.2002.1533","volume":"34","author":"S Lecour","year":"2002","unstructured":"Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN (2002) Identification of novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 34:509\u2013518","journal-title":"J Mol Cell Cardiol"},{"key":"2091_CR25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0889-8529(18)30028-8","volume":"24","author":"EA Espiner","year":"1995","unstructured":"Espiner EA, Richards AM, Yandle TG, Nicholls MG (1995) Natriuretic hormones. Endocrinol Metab Clin N Am 24:481\u2013509","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2091_CR26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1530\/eje.0.1490555","volume":"149","author":"A Niessner","year":"2003","unstructured":"Niessner A, Ziegler S, Slany J, Billensteiner E, Woloszczuk W, Geyer G (2003) Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids? Eur J Endocrinol 149:555\u2013559","journal-title":"Eur J Endocrinol"},{"key":"2091_CR27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","volume":"138","author":"HJ Kwon","year":"2003","unstructured":"Kwon HJ, Cot\u00e9 TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807\u2013811","journal-title":"Ann Intern Med"},{"key":"2091_CR28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1757-1626-2-147","volume":"2","author":"M Singh","year":"2009","unstructured":"Singh M, Diwan MM, Patel KCR (2009) A rare case of supraventricular tachycardia induced by infliximab: a case report. Cases J 2:147\u2013150","journal-title":"Cases J"},{"key":"2091_CR29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/kem336","volume":"47","author":"Y Sote","year":"2008","unstructured":"Sote Y, Green S, Maddison P (2008) Complete heart block after infliximab therapy. Rheumatology 47:227\u2013228","journal-title":"Rheumatology"},{"key":"2091_CR30","first-page":"289","volume":"101","author":"G Bragagni","year":"2010","unstructured":"Bragagni G, Lari F, Magenta G, Brogna R, Zoli G (2010) Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies. Recenti Prog Med 101:289\u2013292","journal-title":"Recenti Prog Med"},{"issue":"2","key":"2091_CR31","first-page":"CD008794","volume":"16","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16(2):CD008794","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-012-2091-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2091-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T05:47:02Z","timestamp":1562219222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-012-2091-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,26]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s10067-012-2091-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,26]]}}}